



IMS Health APAC Q4 POST Newsletter

In this edition, we review trends, dynamics and recent insights into the healthcare industry, globally and across Asia Pacific. We also present the latest news and thought leadership from within IMS Health.

Contents include:

- [ASIA-PACIFIC INSIGHTS](#)
- [DRUG PRICING](#)
- [THOUGHT LEADERSHIP](#)

Asia-Pacific Insights

South Korea:

ATP price cuts to be announced in Feb and implemented in Mar 2016

The Ministry of Health and Welfare (MOHW) has announced that the actual transaction price (ATP) price cuts will be announced on 1st February 2016, rather than 1st January 2016. This is a result of the additional time needed to re-assess pricing data and recalculate the weighted average reductions in price stemming from the ATP provisions of the Rewards for Saving Drug Expenditure (RSDE) system. Nevertheless, the provisions will still be implemented with effect from 1st March 2016 as planned.

India:

New biosimilar guidelines in development

The Indian Ministry of Health and Family Welfare (MOHFW) is developing new guidelines for the approval of biosimilar drugs that will be aligned more closely with regulations seen in other countries. The Ministry is about to release a draft for stakeholder consultation that will build on the current guidelines issued by the Central Drugs Standard Control Organization (CDSCO) and the Ministry of Science and Technology’s Department of Biotechnology (DBT) in 2012. Additional focus on the demonstration of comparability with the reference biologic and on pharmacovigilance and post-marketing surveillance will be included. The Ministry intends to finalize the new guidelines by the end of 2015.

Drug pricing

Global variation in cancer drug prices

A new study published in the Lancet Oncology has revealed significant variation in the prices of cancer medicines globally. The study compared prices for 31 cancer drugs across 16 European countries, as well as Australia and New Zealand. One of the key findings was that patients in New Zealand pay significantly more than their Australian counterparts for some medicines. [LEARN MORE](#)

Thought Leadership

Global medicines use in 2020: outlook and implications

In this report, we provide an outlook on—and the implications of—the use of medicines and spending level in 2020. We take a global view of the markets for all types of pharmaceuticals, including small and large molecules, brands and generics, those dispensed in retail pharmaceuticals as well as those used in hospital or clinic settings. [LEARN MORE](#)



Branded medicine price increases and the impact of off-invoice discounts and rebate

The purpose of this healthcare brief is to draw specific attention to previously published research from the IMS Institute which highlights not only the visible aspects of price increases, but also the less visible off-invoice discounts, rebates, coupons, and other price concessions to payers that often substantially offset these changes in list price. [LEARN MORE](#)

TOP 5 GLOBAL (MAT Q3 2015)

THERAPY CLASSES - ATC

1. L4B Anti-TNF Products
2. A10C Human Insulin & Analogues
3. J5B Antivirals excl anti-HIV
4. C10A Cholest & Trigly Regulator
5. J5C HIV Antivirals

PRODUCTS

1. Harvoni
2. Humira
3. Lantus
4. Enbrel
5. Crestor

CORPORATIONS

1. Novartis
2. Pfizer
3. Sanofi
4. Johnson & Johnson
5. Merck & Co

TOP 5 ASIA-PACIFIC (MAT Q3 2015)

THERAPY CLASSES - ATC

1. V3B Kanpo + Chinese Medicines
2. J1D Cephalosporins & Combs
3. A2B Anti-ulcerants
4. C10A Cholesterol & Triglyceride Regulators
5. J1C Broad Spectrum Penicillins

PRODUCTS

1. Lipitor
2. Plavix
3. Shen Jie
4. Baraclude
5. Nexium

CORPORATIONS

1. Pfizer
2. Novartis
3. Sanofi
4. Astrazeneca
5. GlaxoSmithKline

IMS Health Insights App

One stop for Healthcare Insights

Mobile access to a full range of Healthcare thought leadership publication

Download now from iTunes on <http://buff.ly/1feBZB8> or to your android device on <http://buff.ly/1feC1ZR>

